Evidence map›Paper›PMID 31161859›Full record

ReviewmAbs

Using bispecific antibodies in forced degradation studies to analyze the structure-function relationships of symmetrically and asymmetrically modified antibodies.

Adam R Evans, Michael T Capaldi, Geetha Goparaju, David Colter, Frank F Shi, Sarah Aubert, Lian-Chao Li, Jingjie Mo, Michael J Lewis, Ping Hu and 2 more

Open access · goldAbstract readReviewVideo-Audio Media
In one paragraph

Review in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Toward Drug-Like Multispecific Antibodies by Design.International journal of molecular sciences · 2020
    Review
  8. High-throughput antibody screening from complex matrices using intact protein electrospray mass spectrometry.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Adam R Evansa Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.
Michael T Capaldia Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.
Geetha Goparajua Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.ORCID 0000-0003-1041-7742
David Coltera Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.ORCID 0000-0003-2104-0450
Frank F Shia Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.ORCID 0000-0001-5990-0255
Sarah Auberta Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.ORCID 0000-0003-1276-7703
Lian-Chao Lia Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.
Jingjie Moa Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.
Michael J Lewisa Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.
Ping Hua Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.
Pedro Alfonsoa Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.ORCID 0000-0001-8442-1459
Promod Mehndirattaa Discovery and Manufacturing Sciences, Janssen Research and Development, LLC , Malvern , PA , USA.
Janssen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Forced degradation experiments of monoclonal antibodies (mAbs) aid in the identification of critical quality attributes (CQAs) by studying the impact of post-translational modifications (PTMs), such as oxidation, deamidation, glycation, and isomerization, on biological functions. Structure-function characterization of mAbs can be used to identify the PTM CQAs and develop appropriate analytical and process controls. However, the interpretation of forced degradation results can be complicated because samples may contain mixtures of asymmetrically and symmetrically modified mAbs with one or two modified chains. We present a process to selectively create symmetrically and asymmetrically modified antibodies for structure-function characterization using the bispecific DuoBody® platform. Parental molecules mAb1 and mAb2 were first stressed with peracetic acid to induce methionine oxidation. Bispecific antibodies were then prepared from a mixture of oxidized or unoxidized parental mAbs by a controlled Fab-arm exchange process. This process was used to systematically prepare four bispecific mAb products: symmetrically unoxidized, symmetrically oxidized, and both combinations of asymmetrically oxidized bispecific mAbs. Results of this study demonstrated chain-independent, 1:2 stoichiometric binding of the mAb Fc region to both FcRn receptor and to Protein A. The approach was also applied to create asymmetrically deamidated mAbs at the asparagine 330 residue. Results of this study support the proposed 1:1 stoichiometric binding relationship between the FcγRIIIa receptor and the mAb Fc. This approach should be generally applicable to study the potential impact of any modification on biological function.

Indexed as

Antibodies, BispecificAntibodies, MonoclonalAsparagineHumansImmunoglobulin GMass SpectrometryMethionineOxidation-ReductionReceptors, IgGStructure-Activity RelationshipAntibodies, BispecificAntibodies, MonoclonalAsparagineFCGR3A protein, humanImmunoglobulin GMethionineReceptors, IgGasymmetric antibodiesduobody®Fcmass spectrometrymethionine oxidationMonoclonal antibodyprotein A separationsingle chain modificationstructure function characterization

Identifiers

PMID31161859
PMCPMC6748611
OpenAlexW2948798149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.